Clinical Trials · NCT02278120
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 672
- Start date
- Nov 2014
- Locations
- 183 sites, 30 countries
- Primary endpoint
- Progression Free Survival (PFS) by Investigator Assessment